Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma

NCT02025881 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

High-risk Medulloblastoma

Interventions

DRUG: Carboplatin + etoposide
DRUG: Thiotepa
DRUG: Cyclophosphamide + Busilvex
DRUG: Temozolimide + Irinotecan
COMBINATION_PRODUCT: Etoposide + radiotherapy
DRUG: Temozolomide

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris